Pharma BD Deal Intelligence
Allergan 8-K exhibit announcing the licensing agreement to obtain exclusive worldwide rights to Merck's CGRP migraine development program, $250 million upfront…
Reports Allergan will acquire exclusive worldwide rights to Merck's investigational oral CGRP receptor antagonists for the treatment and prevention of migraine…
Atogepant's Phase 3 success validated Allergan's CGRP thesis despite intensifying mAb competition from Aimovig, Emgality, and Ajovy launching ahead of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Allergan acquired exclusive worldwide rights to Merck's small-molecule oral CGRP receptor antagonist portfolio for $250M upfront plus undisclosed development and commercial milestones. Programs later approved as Ubrelvy (ubrogepant, 2019) and Qulipta (atogepant, 2021).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) (this deal) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
| Allergan plc / Anterios, Inc. | 2016 | $90M | 19 |
← Browse all deals · How we score deals
More: 2015 deals · Allergan plc deals · Neurology deals